Dr Tan Chee WahSenior Research Fellow, Programme in Emerging Infectious DiseasesDuke-NUS Medical School
Dr. Tan Chee Wah is a senior research fellow in Professor Wang Linfa ‘s lab, mainly working on bat-borne viruses, including bat filoviruses, coronaviruses, and orthoreoviruses. During the COVID-19 pandemic, he led the invention of the SARS-CoV-2 surrogate neutralization test, which was commercialized by Genscript under the trade name cPassTM and was the first serology test for SARS-CoV-2 neutralizing antibodies (NAbs) that was granted US FDA EUA approval. Since then, he has established a sophisticated multiplex sVNT, which can detect NAbs against SARS-CoV-2 variants of concern and other SARS-related coronaviruses. This led to his discovery of pan-sarbecovirus immunity in SARS survivors who received BNT162b2 mRNA vaccine.
Contagion & Containment, 7 October 2022, 1000 - 1130 hrsBroad Spectrum COVID Vaccines
Neutralizing antibody (NAb) levels are highly predictive of immune protection from symptomatic infection and severe disease. The unprecedented degree of neutralizing antibody escaped by SARS-CoV-2 Omicron highlights the need of broad-spectrum COVID-19 vaccines. Here, we describe the use of SARS-CoV-2 surrogate Virus Neutralisation test (sVNT) on the key breakthrough’s discovery of the pan-sarbecovirus immunity in BNT162b2-vaccinated SARS survivors and how we translate this discovery to a cross-clade boosting vaccination strategy that elicits broad-spectrum neutralizing antibodies.
Return to Speakers >